Thanks in advance for evaluating my essay!
The following appeared in an article in a consumer-products magazine:
“Two of today’s best-selling brands of full-strength prescription medication for the relief of excess stomach acid, AcidEase and Pepticaid, are now available in milder nonprescription forms. Doctors have written 76 million more prescriptions for full-strength Acid-Ease than for full-strength Pepticaid. So people who need an effective but milder nonprescription medication for the relief of excess stomach acid should choose Acid-Ease.”
My answer: The argument claims that people who need an effective nonprescription medication for the relief of excess stomach acid should choose Acid-Ease. Stated in this way, it fails to consider several important factors that could call the conclusion into question and rests on assumptions for which there is no clear evidence. Thus, the argument is flawed and unconvincing.
First, the argument assumes that there are no significant differences between Acid-Ease and Pepticaid. This is a stretch because many factors could have caused the discrepancy in the number of prescriptions written. The argument fails to consider the context of the medications’ respective releases. For example, if Acid-Ease was released years before Pepticaid, then it would make sense that there have been more prescriptions of Acid-Ease written. Additionally, it’s possible that they are sold at significantly different prices, which would affect patients’ purchasing decisions. Doctors may have been incentivized to prescribe Acid-Ease over Pepticaid as well. Without information that confirms any of these possibilities, the fact alone that more prescriptions of Acid-Ease have been written is not convincing at all.
Second, the argument is using evidence about the prescription strength versions of the drugs to draw a conclusion about the milder, nonprescription strength version of the drugs. This is a risky and questionable extrapolation to make because the nonprescription and prescription versions may differ in unknown ways. While more prescriptions of strength Acid-Ease have been written, nonprescription Acid-Ease may not be as effective or favored by users. If the argument had provided evidence, such as from clinical trials, about whether specifically the nonprescription version of Acid-Ease was indeed better than that of Pepticaid based on the most relevant and holistic metrics, the argument would have been more convincing.
Finally, the argument is evaluating the nonprescription strength Acid-Ease in a bubble. It’s comparing Acid-Ease only to Pepticaid when there may be other competitive brands of nonprescription stomach relief medication. If these products from other brands exist, the argument’s comparison of the brands is incomplete and its conclusion that Acid-Ease is the best is thus unconvincing and biased because the playing field for a “fair” assessment of the brands was unfair from the start.
In summary, the argument fails to convince because of faulty evidence that is used to support the conclusion and because of jumps in logic that leave many possibilities open. If the argument had drawn upon the examples and evidence as suggested, these flaws could have been corrected. Without this information, the argument remains unsubstantiated and open to debate.